Art, indeed, consists in the conception of the result to be produced before its realisation in the material.
—Aristotle in De Partibus Animalium (On The Parts Of Animals), 350 BC
Ongoing innovations continue to advance effective surgical primary tumor control and are linked to improved surgical outcomes, minimized patient morbidity, and better quality of life. The term “oncoplastic” was first used in 1996.1,2 It originates from the Greek words onkos (ογκοσ), meaning bulk, mass, or tumor; and plastikos (πλαςτικóσ), meaning molded or shaped. These words together mean the molding of a tumor. This term is therefore unsatisfactory when applied to the combination of oncology surgery and plastic surgery.
Surgery is the oldest modality of cancer therapy and still forms the mainstay of treatment for solid tumors. Surgery operates by zero-order kinetics, in which all excised cells are killed. Ablation derives from the Latin ablatus, the irregular past participle of auferre, to carry away (ab-, away; plus latus, carried); it now has a specifically surgical edge, and today it applies principally to the surgical removal of any part of the body.3
During the past two decades, major improvements in both operative technique and the use of combined-modality therapy have significantly reduced the morbidity and mortality associated with the surgical treatment of solid neoplasms. For example, breast-preserving surgery has become an alternative to mastectomy in patients with breast carcinoma, and limb salvage is often possible in patients with bone and soft-tissue sarcomas. Advances in microvascular surgery now permit the free transfer of complex autologous tissues, such as free jejunal grafts to reconstitute the upper aerodigestive system or osteomyocutaneous flaps to reconstruct extremities and other mobile body parts such as the jaw.
Intuitively, it appears logical that the term “postablative reconstruction” is an appropriate term for the specialized art of surgery devoted to the restoration of form and function after the surgical removal of solid tumors.
Sammy Al-Benna, M.R.C.S., Ph.D.
Lars Steinsträßer, M.D.
Klinik für Plastische Chirurgie und Schwerbrandverletzte
BG Kliniken Bergmannsheil
1.Hüter J. Tumor-adapted oncoplastic mastopexy and reduction-plasty (in German). Zentralbl Gynakol.
2.Gabka CJ, Bohmert H. Future prospects for reconstructive surgery in breast cancer. Semin Surg Oncol.
Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:
Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.
We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.